International COVID-19 Vaccines Safety Tracking Study (CoVaST-RU): Participation of the Russian Federation
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F21%3A00124034" target="_blank" >RIV/00216224:14110/21:00124034 - isvavai.cz</a>
Result on the web
<a href="https://www.mediasphera.ru/issues/profilakticheskaya-meditsina/2021/12/1230549482021121031?clear_cache=Y" target="_blank" >https://www.mediasphera.ru/issues/profilakticheskaya-meditsina/2021/12/1230549482021121031?clear_cache=Y</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.17116/profmed20212412131" target="_blank" >10.17116/profmed20212412131</a>
Alternative languages
Result language
angličtina
Original language name
International COVID-19 Vaccines Safety Tracking Study (CoVaST-RU): Participation of the Russian Federation
Original language description
Side effects associated with COVID-19 vaccines play a crucial role in the public decision regarding the importance and necessity of vaccination. Objective. Global active surveillance of the safety and efficacy of COVID-19 vaccines. The importance of participation of the Russian Federation is determined by obtaining data on the efficacy and safety of vaccines approved for use in the country, such as GamCOVID-Vac (Sputnik V), EpiVacCorona, CoviVac, and Sputnik Light, and comparing them with vaccines used abroad. Material and methods. The international study includes 3 phases to evaluate vaccine efficacy and safety in target populations. The first phase will study adverse reactions associated with primary vaccination, the second phase will investigate the side effects of booster doses, and the third phase will assess the long-term safety and efficacy of COVID-19 vaccines. Validated electronic questionnaires completed by the target population will be used for data collection. Expected results. The study will provide evidence-based data on the efficacy and safety of domestic vaccines in comparison with foreign vaccines. The study protocol is registered at ClinicalTrials.gov under the identifier NCT04834869. Russian Federation (CoVaST-RU) is included in the study on 26 July 2021.
Czech name
—
Czech description
—
Classification
Type
J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database
CEP classification
—
OECD FORD branch
30304 - Public and environmental health
Result continuities
Project
—
Continuities
S - Specificky vyzkum na vysokych skolach
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Profilakticheskaya meditsina
ISSN
2305-4948
e-ISSN
—
Volume of the periodical
24
Issue of the periodical within the volume
12
Country of publishing house
RU - RUSSIAN FEDERATION
Number of pages
10
Pages from-to
31-40
UT code for WoS article
—
EID of the result in the Scopus database
2-s2.0-85128414532